Rare diseases
Investigational molecules
Locations
Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer
AustriaZanidatamab, tucatinib, capecitabine or eribulin mesylate in HER2-positive advanced breast cancer in adults
SpainComparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer
AustriaStudy on Trastuzumab, Pertuzumab, and Tucatinib for Patients with Stage II-III HER2-Positive Breast Cancer Without Chemotherapy
The NetherlandsStudy on Tucatinib, Capecitabine, and Trastuzumab for Patients with HER2-Positive Breast Cancer and Leptomeningeal Metastases
FranceStudy of Tucatinib, Etoposide, and Trastuzumab for Patients with Metastatic HER2+ Breast Cancer After Progression or Capecitabine Toxicity
FranceStudy of tucatinib and trastuzumab for patients with HER3-mutant and HER2-not amplified metastatic breast cancer
FranceStudy on Post-Surgery Treatment for Colon Cancer Patients Using Trifluridine, Irinotecan, and Drug Combination
ItalyStudy of Disitamab Vedotin and Tucatinib for Patients with Advanced Breast Cancer or Gastric Cancer
FranceStudy of Tucatinib and Ado-Trastuzumab Emtansine for Patients with Advanced HER2+ Breast Cancer
BelgiumStudy of tucatinib, pertuzumab and trastuzumab combination for patients with HER2-positive metastatic breast cancer who have brain metastases after local therapy
FranceStudy of Tucatinib and Trastuzumab for Patients with Advanced Solid Tumors with HER2 Changes
BelgiumTell us about your condition – we search every trial in Europe and connect you with the right site.
